JPWO2020206115A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020206115A5
JPWO2020206115A5 JP2021559064A JP2021559064A JPWO2020206115A5 JP WO2020206115 A5 JPWO2020206115 A5 JP WO2020206115A5 JP 2021559064 A JP2021559064 A JP 2021559064A JP 2021559064 A JP2021559064 A JP 2021559064A JP WO2020206115 A5 JPWO2020206115 A5 JP WO2020206115A5
Authority
JP
Japan
Prior art keywords
aso
seq
angptl2
conjugate
lna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524218A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/026379 external-priority patent/WO2020206115A2/en
Publication of JP2022524218A publication Critical patent/JP2022524218A/ja
Publication of JPWO2020206115A5 publication Critical patent/JPWO2020206115A5/ja
Pending legal-status Critical Current

Links

JP2021559064A 2019-04-03 2020-04-02 Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用 Pending JP2022524218A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962828864P 2019-04-03 2019-04-03
US62/828,864 2019-04-03
PCT/US2020/026379 WO2020206115A2 (en) 2019-04-03 2020-04-02 Angptl2 antisense oligonucleotides and uses thereof

Publications (2)

Publication Number Publication Date
JP2022524218A JP2022524218A (ja) 2022-04-28
JPWO2020206115A5 true JPWO2020206115A5 (es) 2023-04-10

Family

ID=70465458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559064A Pending JP2022524218A (ja) 2019-04-03 2020-04-02 Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用

Country Status (13)

Country Link
US (1) US20220213484A1 (es)
EP (1) EP3947680A2 (es)
JP (1) JP2022524218A (es)
KR (1) KR20210149107A (es)
CN (1) CN113906139A (es)
AU (1) AU2020252374A1 (es)
BR (1) BR112021019182A2 (es)
CA (1) CA3135794A1 (es)
EA (1) EA202192733A1 (es)
IL (1) IL286826A (es)
MX (1) MX2021012098A (es)
SG (1) SG11202110745VA (es)
WO (1) WO2020206115A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3131970B1 (fr) 2022-01-14 2024-02-23 Univ D’Aix Marseille Amu Dispositif pour la simulation en chirurgie abdominale

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP1331011A3 (en) 1991-10-24 2003-12-17 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
DE04020014T1 (de) 1997-09-12 2006-01-26 Exiqon A/S Bi-zyklische - Nukleosid,Nnukleotid und Oligonukleotid-Analoga
JPH11341989A (ja) * 1998-03-31 1999-12-14 Sanyo Electric Co Ltd Ｄｎａ断片増幅方法、ｄｎａ断片増幅装置、微生物群測定方法、微生物群分析方法および汚染物質測定方法
BRPI0008131B8 (pt) 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
PT1178999E (pt) 1999-05-04 2007-06-26 Santaris Pharma As Análogos de l-ribo-lna
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US7687617B2 (en) 2002-11-18 2010-03-30 Santaris Pharma A/S Oligonucleotides with alternating segments of locked and non-locked nucleotides
DK2141234T3 (en) 2003-03-21 2016-06-20 Roche Innovation Ct Copenhagen As Short interfering RNA (siRNA) analogues
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
PL1984381T3 (pl) 2006-01-27 2011-03-31 Isis Pharmaceuticals Inc Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
EP1984382B1 (en) 2006-01-27 2012-08-15 Santaris Pharma A/S Lna modified phosphorothiolated oligonucleotides
WO2007107162A2 (en) 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
US7547684B2 (en) 2006-05-11 2009-06-16 Isis Pharmaceuticals, Inc. 5′-modified bicyclic nucleic acid analogs
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US8278426B2 (en) 2007-06-08 2012-10-02 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2009006478A2 (en) 2007-07-05 2009-01-08 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
EP2963116B1 (en) * 2009-03-04 2020-11-11 CuRNA, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
EP2490699A1 (en) 2009-10-20 2012-08-29 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
WO2011156202A1 (en) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
DK2751270T3 (en) 2011-08-29 2018-10-29 Ionis Pharmaceuticals Inc OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
BR112015010116A2 (pt) 2012-11-15 2017-08-22 Roche Innovation Ct Copenhagen As COMPOSTOS CONJUGADOS ANTI-SENTIDO ANTI-ApoB
WO2014167529A1 (en) * 2013-04-10 2014-10-16 Institut De Cardiologie De Montreal Methods and compositions for preventing and treating atherosclerosis
MX2015015239A (es) 2013-05-01 2016-10-03 Ionis Pharmaceuticals Inc Composiciones y metodos.
RS59986B1 (sr) 2013-06-27 2020-03-31 Roche Innovation Ct Copenhagen As Antisens oligomeri i konjugati koji ciljno deluju na pcsk9
DK3253875T3 (da) * 2015-02-04 2020-04-14 H Hoffmann La Roche Ag Tau-antisense-oligomerer og anvendelser deraf
AU2017363892B2 (en) 2016-11-23 2023-06-15 Alnylam Pharmaceuticals, Inc. Modified RNA agents with reduced off-target effect

Similar Documents

Publication Publication Date Title
JP7500426B2 (ja) Ｃａｍｋ２ｄアンチセンスオリゴヌクレオチドおよびその使用
JPWO2019165067A5 (es)
CA3004799C (en) Oligonucleotides for inducing paternal ube3a expression
AU2005244764B2 (en) Modulation of glucose-6-phosphatase translocase expression
JP2022106727A5 (es)
JP2016530882A5 (es)
JP2012050438A5 (es)
RU2017127609A (ru) Антисмысловые олигомеры тау-белка и их применение
JP2011504362A5 (es)
EP2256200A2 (en) Modulation of eIF4E expression
JP2010524486A5 (es)
JP7348922B2 (ja) Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子
WO2010120969A1 (en) Targeting of the mir-30 family and let-7 family as a treatment for heart disease
JP2011526482A5 (es)
RU2020121752A (ru) Средство для лечения синдрома ангельмана на основе антисмысловой нуклеиновой кислоты
JP2021505129A5 (es)
JP2009513112A (ja) アラビノース修飾ヌクレオチドを含む低分子干渉リボ核酸二重鎖
WO2022173826A1 (en) Antisense oligonucleotides increasing foxg1 expression
CN110536965B (zh) 用于抑制男性型脱发靶基因表达的不对称siRNA
JPWO2020206115A5 (es)
EP2023938A2 (en) Modulation of chrebp expression
CN117363614A (zh) 抑制血管紧张素原表达的siRNA及其用途
JP2021522346A (ja) 治療での使用及び方法
CN114829599A (zh) Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途
JPWO2019140236A5 (es)